vs
CITIUS ONCOLOGY, INC.（CTOR）与CaliberCos Inc.（CWD）财务数据对比。点击上方公司名可切换其他公司
CaliberCos Inc.的季度营收约是CITIUS ONCOLOGY, INC.的1.0倍（$4.1M vs $3.9M），CITIUS ONCOLOGY, INC.净利率更高（-140.3% vs -188.3%，领先48.0%）
Citius Oncology是一家处于后期阶段的生物制药企业，专注于开发针对癌症患者的创新靶向疗法，核心管线覆盖血液恶性肿瘤和实体瘤领域的未满足医疗需求，主要服务北美及全球肿瘤诊疗市场。
CaliberCos Inc.是一家总部位于美国的另类资产管理企业，核心业务涵盖房地产投资、资产运营及增值开发板块，服务对象包含机构投资者、高净值人群与零售投资者，业务布局主要集中在北美地区。
CTOR vs CWD — 直观对比
营收规模更大
CWD
是对方的1.0倍
$3.9M
净利率更高
CTOR
高出48.0%
-188.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.9M | $4.1M |
| 净利润 | $-5.5M | $-7.7M |
| 毛利率 | 80.0% | — |
| 营业利润率 | -133.2% | -196.6% |
| 净利率 | -140.3% | -188.3% |
| 营收同比 | — | -52.5% |
| 净利润同比 | 16.9% | 32.2% |
| 每股收益（稀释后） | $-0.06 | $1.95 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTORCWD
| Q4 25 | $3.9M | $4.1M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $5.1M | ||
| Q1 25 | — | $7.3M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | — | $8.2M | ||
| Q1 24 | — | $23.0M |
净利润CTORCWD
| Q4 25 | $-5.5M | $-7.7M | ||
| Q3 25 | — | $-4.4M | ||
| Q2 25 | — | $-5.3M | ||
| Q1 25 | — | $-4.4M | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $146.0K | ||
| Q2 24 | — | $-4.7M | ||
| Q1 24 | — | $-3.8M |
毛利率CTORCWD
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率CTORCWD
| Q4 25 | -133.2% | -196.6% | ||
| Q3 25 | — | -129.6% | ||
| Q2 25 | — | -112.4% | ||
| Q1 25 | — | -62.7% | ||
| Q4 24 | — | -236.8% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | -65.0% | ||
| Q1 24 | — | -22.9% |
净利率CTORCWD
| Q4 25 | -140.3% | -188.3% | ||
| Q3 25 | — | -120.2% | ||
| Q2 25 | — | -104.5% | ||
| Q1 25 | — | -60.7% | ||
| Q4 24 | — | -247.6% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | -57.8% | ||
| Q1 24 | — | -16.6% |
每股收益（稀释后）CTORCWD
| Q4 25 | $-0.06 | $1.95 | ||
| Q3 25 | — | $-1.65 | ||
| Q2 25 | — | $-4.15 | ||
| Q1 25 | — | $-3.85 | ||
| Q4 24 | — | $-10.15 | ||
| Q3 24 | — | $0.12 | ||
| Q2 24 | — | $-4.34 | ||
| Q1 24 | — | $-3.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.3M | $2.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $58.4M | $1.3M |
| 总资产 | $110.0M | $135.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTORCWD
| Q4 25 | $7.3M | $2.9M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $683.0K | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $2.1M |
股东权益CTORCWD
| Q4 25 | $58.4M | $1.3M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $-19.9M | ||
| Q1 25 | — | $-15.8M | ||
| Q4 24 | — | $-12.6M | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | $-4.7M | ||
| Q1 24 | — | $-745.0K |
总资产CTORCWD
| Q4 25 | $110.0M | $135.4M | ||
| Q3 25 | — | $82.6M | ||
| Q2 25 | — | $59.3M | ||
| Q1 25 | — | $103.6M | ||
| Q4 24 | — | $105.5M | ||
| Q3 24 | — | $158.6M | ||
| Q2 24 | — | $195.2M | ||
| Q1 24 | — | $201.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-7.4M | $-12.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CTORCWD
| Q4 25 | $-7.4M | $-12.1M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $555.0K | ||
| Q3 24 | — | $-74.0K | ||
| Q2 24 | — | $1.4M | ||
| Q1 24 | — | $-1.5M |
现金转化率CTORCWD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.51× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
